ClinConnect ClinConnect Logo
Search / Trial NCT06962007

Sugammadex-Induced Clenching During Neuromuscular Blockade Reversal

Launched by WONKWANG UNIVERSITY HOSPITAL · Apr 29, 2025

Trial Information

Current as of July 01, 2025

Not yet recruiting

Keywords

Sugammadex Mouth Clenching Neuromuscular Blockade Reversal

ClinConnect Summary

This clinical trial is looking at a specific issue that can happen when a medication called sugammadex is used to reverse muscle relaxation during surgery. Specifically, the study wants to understand how often and how severely patients might experience mouth clenching, known as masseter muscle spasm, after receiving sugammadex. Researchers will involve adult patients aged 19 to 70 who are undergoing planned surgeries with a certain anesthetic called rocuronium. Participants will be randomly assigned to receive different doses of sugammadex or an alternative treatment, and the study will carefully observe and measure any clenching that occurs within 10 minutes after the muscle relaxation is reversed.

To take part in this trial, individuals must be generally healthy (classified as ASA physical status I-II) and not have any neuromuscular disorders, kidney issues, or prior dental problems that could affect the results. The goal of the study is to find ways to make surgery safer by identifying factors that might increase the risk of this clenching, which will help doctors adjust treatments accordingly. If you or a loved one is considering participating, it’s an opportunity to contribute to important research that could improve patient care during surgeries.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Eligible participants are adults aged 19-70 years, American Society of Anesthesiologists (ASA) physical status I-II, undergoing elective surgery under general anesthesia with rocuronium.
  • Exclusion Criteria:
  • Exclusion criteria include neuromuscular disorders, renal impairment (creatinine clearance \< 30 mL/min), history of clenching or dental disease, allergy to study drugs, or emergency surgery.

About Wonkwang University Hospital

Wonkang University Hospital is a leading healthcare institution dedicated to advancing medical research and clinical excellence. As a prominent sponsor of clinical trials, the hospital is committed to enhancing patient care through innovative studies that explore new treatment modalities and therapeutic interventions. With a robust infrastructure and a multidisciplinary team of experienced researchers and healthcare professionals, Wonkang University Hospital prioritizes patient safety and ethical standards while fostering collaborations that aim to translate scientific discoveries into effective clinical practices. The hospital’s focus on rigorous research methodologies and patient-centered approaches positions it as a key contributor to the advancement of medical knowledge and public health.

Locations

Iksan, Jeonbuk Do, Korea, Republic Of

Patients applied

0 patients applied

Trial Officials

Cheolhyeong Lee, MD

Principal Investigator

Wonkwang University Hospital

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported